Literature DB >> 6322966

Metastases to the female genital tract. Analysis of 325 cases.

M T Mazur, S Hsueh, D J Gersell.   

Abstract

In order to better define the frequency and patterns of metastasis to the female genital tract, all cases of nonhematopoietic metastases to the adnexa, uterus, vagina, and vulva encountered in patients treated at Barnes Hospital between 1950 and 1981 were reviewed. Three hundred twenty-five metastatic cancers from 269 patients were recovered. One hundred forty-nine cases were from extragenital primaries; the remaining tumors were intragenital metastases. Ovary and vagina were the most frequent metastatic sites for both extragenital and genital primaries. The majority of the extragenital metastases were adenocarcinomas from the gastrointestinal tract, but a variety of other primaries did spread, on occasion, to the genital tract. Twenty-seven percent of the metastases presented as possible primary gynecologic lesions, and 75% of these tumors had an extragenital origin. It is shown that despite certain trends in the distribution of metastases, all sites in the female genital tract are at risk for the occurrence of metastases.

Entities:  

Mesh:

Year:  1984        PMID: 6322966     DOI: 10.1002/1097-0142(19840501)53:9<1978::aid-cncr2820530929>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  67 in total

1.  Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy.

Authors:  Joseph Menczer; Angela Chetrit; Siegal Sadetzki
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Malignant paraganglioma of the uterus.

Authors:  A Beham; C Schmid; C D Fletcher; L Auböck; H Pickel
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

3.  Oophorectomy in primary colorectal cancer.

Authors:  A Schofield; J Pitt; G Biring; P M Dawson
Journal:  Ann R Coll Surg Engl       Date:  2001-03       Impact factor: 1.891

4.  Secondary malignancies of the uterine cervix: a potential diagnostic pitfall.

Authors:  Gian Franco Zannoni; Valerio Gaetano Vellone; Marco Petrillo; Guido Fadda; Esther Diana Rossi; Giovanni Scambia; Arnaldo Carbone
Journal:  Virchows Arch       Date:  2013-06-10       Impact factor: 4.064

5.  Ovarian metastasis from breast invasive ductal carcinoma.

Authors:  P Gavriilidis; A Ananiadis; V Theodoulidis; I Toskas; S Barbanis
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

6.  Would extirpative pelvic surgery improve survival in gynecological metastases of lung cancer? Case report and review of the literature.

Authors:  Lusine Sevinyan; Marianne Illsley; Ben Haagsma; Simon Butler-Manuel; Patricia Ellis; Thumuluru Kavitha Madhuri
Journal:  Int Cancer Conf J       Date:  2020-09-13

7.  Clinicopathological characteristics of fallopian tube metastases from primary endometrial, cervical, and nongynecological malignancies: a single institutional experience.

Authors:  Kiyong Na; Hyun-Soo Kim
Journal:  Virchows Arch       Date:  2017-07-13       Impact factor: 4.064

8.  Challenging diagnosis of a jejunal adenocarcinoma with ovarian metastasis: report of an unusual case.

Authors:  Yang Yang Huang; Jeremy John Pratt; Marcus Dabner; William Tjhin
Journal:  BMJ Case Rep       Date:  2013-04-10

9.  Unusual case of subcutaneous angiosarcoma metastatic to the ovary.

Authors:  David Cantú De León; Delia Pérez Montiel; José Chanona Vilchis
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

10.  A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer.

Authors:  Jean-Philippe Meyniel; Paul H Cottu; Charles Decraene; Marc-Henri Stern; Jérôme Couturier; Ingrid Lebigot; André Nicolas; Nina Weber; Virginie Fourchotte; Séverine Alran; Audrey Rapinat; David Gentien; Sergio Roman-Roman; Laurent Mignot; Xavier Sastre-Garau
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.